Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
idiopathic pulmonary fibrosis
Biotech
Tvardi's STAT3 inhibitor flunks IPF trial amid high dropout rate
The biotech reported high dropout rates and placebolike efficacy in a phase 2 trial of its idiopathic pulmonary fibrosis prospect.
Nick Paul Taylor
Oct 13, 2025 9:25am
PureTech creates Celea to develop promising lung disease drug
Aug 12, 2025 10:46am
Contineum shifts cash from MS to lung disease showdown with BMS
Aug 6, 2025 9:51am
Boehringer 'crossing fingers' ahead of 2 key FDA approvals
Jul 24, 2025 3:00am
Pliant ends lung disease program over rise in adverse events
Jun 30, 2025 4:49am
Transpire licenses PDE4 inhibitor for lung disease
Jun 3, 2025 9:45am
